Global Irritable Bowel Syndrome Market 2015-2019

過敏性腸症候群(IBS)治療薬の世界市場:便秘型IBS(IBS-C)、下痢型IBS(IBS-D)

◆タイトル:Global Irritable Bowel Syndrome Market 2015-2019
◆商品コード:IRTNTR4709
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年11月19日
◆ページ数:86
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥316,400見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、過敏性腸症候群(IBS)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、過敏性腸症候群(IBS)治療薬の世界市場規模及び予測、作用機序別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Irritable Bowel Syndrome
Irritable bowel syndrome is a common disorder of the digestive system causing abdominal cramps, discomfort, bloating, constipation, and diarrhea. Inflammatory bowel disease, which is a chronic disease with recurrent immune response and inflammation of the GI tract, is sometimes confused with irritable bowel syndrome. The symptoms of irritable bowel syndrome generally appear in a patient aged around 30 years. According to the CDC, prominent symptoms of irritable bowel syndrome include severe bloating, severe stomach cramps or abdominal pain, lower back pain, groin pain, heartburn, acidity, shooting pain in the legs, and lightheadedness after eating.

TechNavio’s analysts forecast the Global Irritable Bowel Syndrome market to grow at a CAGR of 14.04 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Irritable Bowel Syndrome market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of irritable bowel syndrome.
TechNavio’s report, Global Irritable Bowel Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Irritable Bowel Syndrome market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Actavis
• Astellas Pharma
• Nestle
• Takeda Pharmaceutical

[Other Prominent Vendors]
• Abbott
• Alba Therapeutics
• Alfa Wassermann
• Alizyme
• Almirall
• AltheRx Pharmaceuticals
• Ardelyx
• AstraZeneca
• Bayer
• Bristol Myers Squibb
• Dainippon Sumitomo Pharma
• Dong-A Socio Holdings
• Drais Pharmaceuticals
• Dynogen
• gIcare Pharma
• GlaxoSmithKline
• Hanmi Pharmaceuticals
• ImmusanT
• Ironwood
• Janssen
• Lexicon Pharmaceuticals
• Menarini
• MicroDose Therapeutx
• Norgine
• Novartis
• Ocera Therapeutics
• Ono Pharmaceutical
• Par Pharmaceutical
• Pfizer
• Pharmos
• Protagonist Therapeutics
• RaQualia Pharma
• Rottapharm
• Salix
• Seldar Pharma
• Shire
• SK Chemicals
• SOFAR
• Synergy Pharmaceuticals
• Synthetic Biologics
• Tioga Pharmaceuticals
• Tsumura
• Yuhan

[Market Driver]
• Presence of Unmet Need
• For a full, detailed list, view our report

[Market Challenge]
• High Cost of Therapy
• For a full, detailed list, view our report

[Market Trend]
• Rise in Public Awareness
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1.1 Linzess
04.1.2 Irribow/Irribow OD
04.1.3 Lotronex
04.1.4 Amitiza

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Introduction

07.Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis

08.Market Segmentation by Mechanism of Action
08.1 Guanylate Cyclase Receptor-C Agonist
08.2 5HT3 Antagonist
08.3 Chloride Channel Activator
08.4 Others

09.Market Segmentation by Dosage Form
09.1 Solid
09.2 Liquid

10.Market Segmentation by Indication
10.1 IBS-C
10.2 IBS-D

11.Market Segmentation by End User Gender
11.1 Female
11.2 Both

12.Geographical Segmentation

13.Rate of Incidence and Prevalence

14.Buying Criteria

15.Market Growth Drivers

16.Drivers and their Impact

17.Market Challenges

18.Impact of Drivers and Challenges

19.Market Trends

20.Trends and their Impact

21.Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 Takeda
21.2.2 Nestle
21.2.3 Actavis
21.2.4 Astellas
21.3 Other and Future Prominent Vendors

22.Pipeline Portfolio

23.Key Vendor Analysis
23.1 Actavis
23.1.1 Key Facts
23.1.2 Business Description
23.1.3 Business Segmentation
23.1.4 Business Segmentation by Revenue 2012 and 2013
23.1.5 Sales by Geography
23.1.6 Business Strategy
23.1.7 Key Information
23.1.8 SWOT Analysis
23.2 Astellas Pharma
23.2.1 Key Facts
23.2.2 Business Overview
23.2.3 Product Segmentation
23.2.4 Product Segmentation by Revenue 2012 and 2013
23.2.5 Geographical Segmentation by Revenue 2013
23.2.6 Business Strategy
23.2.7 Recent Developments
23.2.8 SWOT Analysis
23.3 Nestlé
23.3.1 Key Facts
23.3.2 Business Overview
23.3.3 Business Segmentation by Revenue 2013
23.3.4 Business Segmentation by Revenue 2012 and 2013
23.3.5 Geographical Segmentation by Revenue 2013
23.3.6 Business Strategy
23.3.7 Recent Developments
23.3.8 SWOT Analysis
23.4 Takeda Pharmaceuticals
23.4.1 Key Facts
23.4.2 Business Overview
23.4.3 Business Segmentation by Revenue 2013
23.4.4 Business Segmentation by Revenue 2013
23.4.5 Geographical Segmentation by Revenue 2013
23.4.6 Business Strategy
23.4.7 Recent Developments
23.4.8 SWOT Analysis

24.Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Global Irritable Bowel Syndrome Market 2014-2019 (US$ million)
Exhibit 3: Global Irritable Bowel Syndrome Market Segmentation by Mechanism of Action
Exhibit 4: Global Irritable Bowel Syndrome Market Segmentation by Mechanism of Action 2014
Exhibit 5: Global Irritable Bowel Syndrome Market Segmentation by Dosage Form
Exhibit 6: Global Irritable Bowel Syndrome Market Segmentation by Dosage Form 2014
Exhibit 7: Global Irritable Bowel Syndrome Market Segmentation by Indication
Exhibit 8: Global Irritable Bowel Syndrome Market Segmentation by Mechanism of Action 2014
Exhibit 9: Global Irritable Bowel Syndrome Market Segmentation by End User Gender
Exhibit 10: Global Irritable Bowel Syndrome Market Segmentation by End User Gender 2014
Exhibit 11: Global Irritable Bowel Syndrome Market by Geographical Segmentation 2014
Exhibit 12: Prevalence of Irritable Bowel Syndrome in Japanese Females, by Type
Exhibit 13: Prevalence of Irritable Bowel Syndrome in Japanese Males, by Type
Exhibit 14: Global Irritable Bowel Syndrome Market Share Analysis 2014
Exhibit 15: Pipeline Portfolio of the Drug Candidates for Irritable Bowel Syndrome
Exhibit 16: Clinical Trials of Irritable Bowel Syndrome Drugs by Geography
Exhibit 17: Clinical Trials of Irritable Bowel Syndrome Drugs by Geography
Exhibit 18: Percentage of Clinical Trial Molecules in Each Phase
Exhibit 19: Actavis: Business Segmentation 2013
Exhibit 20: Actavis: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 21: Actavis : Sales by Geography (in US$ million)
Exhibit 22: Astellas Pharma: Product Segmentation 2013
Exhibit 23: Astellas Pharma : Product Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 24: Astellas Pharma: Geographical Segmentation by Revenue 2013
Exhibit 25: Nestlé: Business Segmentation by Revenue 2013
Exhibit 26: Nestlé: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 27: Nestlé: Geographical Segmentation by Revenue 2013
Exhibit 28: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
Exhibit 29: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
Exhibit 30: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013



【掲載企業】

Actavis, Astellas Pharma, Nestle, Takeda Pharmaceutical, Abbott, Alba Therapeutics, Alfa Wassermann, Alizyme, Almirall, AltheRx Pharmaceuticals, Ardelyx , AstraZeneca, Bayer , Bristol Myers Squibb , Dainippon Sumitomo Pharma, Dong-A Socio Holdings,DraisPharmaceuticals, Dynogen, gIcare Pharma, GlaxoSmithKline , Hanmi Pharmaceuticals, ImmusanT, Ironwood, Janssen, Lexicon Pharmaceuticals, Menarini, MicroDose Therapeutx, Norgine, Novartis, Ocera Therapeutics, Ono Pharmaceutical, ParPharmaceutical, Pfizer, Pharmos, Protagonist Therapeutics, RaQualia Pharma, Rottapharm, Salix, Seldar Pharma, Shire , SK Chemicals, SOFAR , Synergy Pharmaceuticals, Synthetic Biologics, Tioga Pharmaceuticals, Tsumura, Yuhan

【資料のキーワード】

過敏性腸症候群(IBS)、便秘型IBS(IBS-C)、下痢型IBS(IBS-D)、治療薬、製薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[過敏性腸症候群(IBS)治療薬の世界市場:便秘型IBS(IBS-C)、下痢型IBS(IBS-D)] (Global Irritable Bowel Syndrome Market 2015-2019 / IRTNTR4709)販売に関する免責事項
[過敏性腸症候群(IBS)治療薬の世界市場:便秘型IBS(IBS-C)、下痢型IBS(IBS-D)] (Global Irritable Bowel Syndrome Market 2015-2019 / IRTNTR4709)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆